Microorganisms and methods for producing pyruvate, ethanol, and other compounds

ABSTRACT

Microorganisms comprising modifications for producing pyruvate, ethanol, and other compounds. The microorganisms comprise modifications that reduce or ablate activity of one or more of pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, phosphate acetyltransferase, acetate kinase, pyruvate oxidase, lactate dehydrogenase, cytochrome terminal oxidase, succinate dehydrogenase, 6-phosphogluconate dehydrogenase, glutamate dehydrogenase, pyruvate formate lyase, pyruvate formate lyase activating enzyme, and isocitrate lyase. The microorganisms optionally comprise modifications that enhance expression or activity of pyruvate decarboxylase and alcohol dehydrogenase. The microorganisms are optionally evolved in defined media to enhance specific production of one or more compounds. Methods of producing compounds with the microorganisms are provided.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under DE-FC02-07ER64494, DE-SC0008103 awarded by the U.S. Department of Energy. The government has certain rights in the invention.

BACKGROUND

Over the past decade a number of chemical companies have begun to develop infrastructures for the production of compounds using bio-based processes. Considerable progress has been reported toward new processes for producing commodity chemicals such as ethanol, lactic acid, 1,3-propanediol, and adipic acid. In addition, advances have been made in the genetic engineering of microbes for higher value specialty compounds such as acetate, polyketides, and carotenoids.

Pyruvate is a starting material for synthesizing a variety of biofuels and chemicals. Industrially, pyruvate is produced via dehydration and decarboxylation of calcium tartrate, a byproduct of the wine industry. This process involves toxic solvents and is energy intensive with an estimated production cost of $8,650 per ton of pyruvate. Microbial pyruvate production is based primarily upon two microorganisms, a multi-vitamin auxotroph of the yeast T. glabrata and a lipoic auxotroph of E. coli containing an F1ATPase mutation. The estimated cost of pyruvate production via microbial fermentation with such strains is estimated to be $1,255 per ton of pyruvate, an 85% savings. Increasing the yield of pyruvate would increase the savings even further.

Ethanol is mainly of interest as a petrol additive, or substitute, because ethanol-blended fuel produces a cleaner, more complete combustion that reduces greenhouse gas and toxic emissions. The production of ethanol in the US has increased tremendously in recent years, and demand is projected to increase even further. As a consequence of the surge in demand for biofuels, ethanol-producing microorganisms are of considerable interest due to their potential for the production of bioethanol. To keep in step with the growing demand for biofuels, the engineering of new strains of fermentative microorganisms that can efficiently produce ethanol will be required.

There is a need for microorganisms that efficiently produce pyruvate, ethanol, or other commodity chemicals.

SUMMARY OF THE INVENTION

The present invention addresses the aforementioned needs by providing microorganisms with increased production of pyruvate, ethanol, or other commodity chemicals. Methods of producing commodity chemicals with the microorganisms described herein are also provided.

One aspect of the invention is a microorganism comprising modifications that reduce or ablate activity of one or more enzymes in a first set, one or more enzymes in a second set, and enzymes in a third set. The enzymes in the first set are selected from the group consisting of pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase. The enzymes in the second set are selected from the group consisting of phosphate acetyltransferase, acetate kinase, and pyruvate oxidase. The enzymes in the third set comprise lactate dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase; lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; or lactate dehydrogenase, one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase.

In some versions, the one or more enzymes in the second set are selected from the group consisting of phosphate acetyltransferase and pyruvate oxidase.

In some versions, the enzymes in the third set comprise lactate dehydrogenase and cytochrome terminal oxidase, lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase, or succinate dehydrogenase and 6-phosphogluconate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from phosphate acetyltransferase, and the enzymes in the third set comprise lactate dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, or lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from phosphate acetyltransferase, and the enzymes in the third set comprise lactate dehydrogenase and cytochrome terminal oxidase, or lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from pyruvate oxidase, and the enzymes in the third set comprise one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the microorganism further comprises a modification that reduces or ablates activity of an enzyme selected from the group consisting of pyruvate formate lyase and pyruvate formate lyase activating enzyme.

In some versions, the microorganism further comprises a modification that enhances expression of pyruvate decarboxylase and alcohol dehydrogenase.

In some versions, the microorganism is a bacterium or a yeast.

In some versions, an evolved microorganism is produced by sequentially culturing any microorganism described above or elsewhere herein in media comprising decreasing concentrations of a compound such as acetate, ethanol, or another compound. The media each preferably comprise approximately a same amount of total consumable carbon. In some versions, the microorganism is cultured in media comprising decreasing concentrations of acetate. The concentrations of acetate in the media may range from about 0.1 mg/L acetate to about 3 g/L acetate.

Another aspect of the invention is a method of producing a chemical. The method comprises culturing any microorganism described above or elsewhere herein. The chemical may be selected from the group consisting of pyruvate and ethanol. The culturing may comprise culturing the microorganism in a medium comprising a biomass hydrolysate.

The objects and advantages of the invention will appear more fully from the following detailed description of the preferred embodiment of the invention made in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schema showing the central metabolic pathway of wild-type E. coli. Genes associated with each reaction in the central metabolic network are shown and flux values are labeled. The metabolic flux distribution for the wild-type strain under aerobic conditions was predicted by flux balance analysis. Glucose uptake rate was set at 10 mmol/gDW/hour. The dashed line represents the ethanol synthesis pathway (PET operon) from Zymomonas mobilis.

FIGS. 2A-2D are schemas showing the central metabolic pathway of mutant E. coli strains designed for pyruvate production. Genes associated with each reaction in the central metabolic network are shown and flux values are labeled. The reactions marked by bars correspond to the deletion targets calculated computationally. The labeled metabolic flux distribution for each strain was predicted by flux balance analysis. Glucose uptake rate was set at 10 mmol/gDW/hour. Oxygen uptake was unlimited for the strains shown in FIGS. 2B-2D, but limited to 3 mmol/gDW/hour for the strain shown in FIG. 2A. FIG. 2A: Strain designed as ΔaceE, ΔcyoA, ΔcydB, Δpta, ΔeutI, ΔidhA, and Δdld. FIG. 2B: Strain designed as ΔlpdA, Δgnd, ΔsdhA, ΔpoxB, ΔpflB, ΔpflD, ΔtdcE, and ΔpurU. FIG. 2C: Strain designed as ΔaceE, ΔgdhA, ΔpoxB, ΔldhA, Δdld, ΔatpE, ΔpflB, ΔpflD, and ΔtdcE. FIG. 2D: Strain designed as designed as ΔaceE, Δgnd, ΔpoxB, ΔldhA, Δdld, ΔatpE, ΔpflB, ΔpflD, and ΔtdcE.

FIGS. 3A-3F show growth (FIGS. 3A and 3D), pyruvate production (FIGS. 3B and 3E), and glucose consumption (FIGS. 3C and 3F) of wild-type (BW25113) and mutant E. coli strains. Cells were grown in M9 minimal medium containing glucose and acetate. (See Table 2 for media details).

FIG. 4 shows (a) lactate and (b) acetate secretion for parent (BW25113) and mutant E. coli strains under aerobic conditions in shake flasks. The shown concentrations are the maximum acid concentrations observed over 60 hours during growth in M9 minimal medium supplemented with glucose and acetate. (See Table 2 for media details). Acetate accumulated in BW25113, PYR001 and PYR002 cultures and lactate accumulated in PYR002 cultures. * indicates concentrations of acetate and lactate that were below the detection level of the HPLC.

FIG. 5 shows growth, glucose consumption, and pyruvate production by PYR004 in bioreactors. Panels (A) and (B) show batch fermentation in minimal salts medium containing 30 g/L glucose with 1.5 g/L acetate (panel A) or 3 g/L acetate (panel B). Panel (C) shows fed-batch fermentation operated in minimal salts medium initially containing 30 g/L glucose and 1.5 g/L acetate. In the fed-batch operation, an additional 7.5 mL of 200 g/L acetate was added at 8.5 hours, indicated by the black arrow, for a total acetate concentration of 3.0 g/L. Experiments were performed in duplicate. Diamond: OD 600. Triangle: glucose concentration. Square: pyruvate concentration.

FIG. 6 shows growth, glucose consumption and pyruvate production by PYR020 in bioreactors. Panels (A) and (B) show batch fermentation in minimal salts medium containing 30 g/L glucose with 0.9 g/L acetate (Panel A) or 1.5 g/L acetate (Panel B). Panel (C) shows fed-batch fermentation operated in minimal salts medium initially containing 30 g/L glucose and 0.6 g/L acetate. In the fed-batch operation, an additional 1.5 mL of 200 g/L acetate was added at 17 hours, indicated by the black arrow. Experiments were performed in duplicate. Diamond: OD 600. Triangle: glucose concentration. Square: pyruvate concentration.

FIG. 7 shows batch production of pyruvate in ammonia fiber expansion (AFEX)-pretreated switchgrass hydrolysate (ASGH) by strain PYR020. Cells were grown in ASGH containing 48 g/L glucose, 27 g/L xylose, and 2.6 g/L acetate. Diamond: OD 600. Square: pyruvate concentration.

FIGS. 8A-8B show product secretion from various strains under anaerobic conditions. Secretion of ethanol, succinate, and formate is shown in FIG. 8A. Secretion of acetate and lactate is shown in FIG. 8B. All experiments were performed anaerobically in hungate tubes in M9 minimal media. Columns marked “a” correspond to fermentations containing 1.98 g/L glucose and 0.02 g/L acetate. Multiple samples were taken over 48 hours, which reduced the culture volume by about 50%. Columns marked (b) correspond to fermentations in M9 medium with 1.98 g/L glucose and 0.02 g/L acetate for 24 hours, but only three samples were taken at 16, 20 and 24 hours. Columns marked (c) correspond to fermentations in M9 minimal medium with more acetate (0.1 g/L) and 1.9 g/L glucose for 24 hours, with only three samples. Error bars represent standard errors among three replicates. Percent of theoretical yield was calculated as the ethanol concentration divided by the theoretical maximum production of ethanol (2 mmol of ethanol per mmol of glucose plus 0.67 mmol of ethanol per mmol of acetate). t-tests were used to determine significant differences in product concentrations between different fermentations (a, b, and c columns) where * and ** indicates the p-value is between 0.01 and 0.05, or less than 0.01, respectively.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the invention is directed to microorganisms comprising modifications that reduce or ablate the activity of gene products of one or more genes. Such a modification that that reduces or ablates the activity of gene products of one or more genes is referred to herein as a “functional deletion” of the gene product. “Gene product” refers to a protein or polypeptide encoded and produced by a particular gene. “Gene” refers to a nucleic acid sequence capable of producing a gene product and may include such genetic elements as a coding sequence together with any other genetic elements required for transcription and/or translation of the coding sequence. Such genetic elements may include a promoter, an enhancer, and/or a ribosome binding site (RBS), among others.

One of ordinary skill in the art will appreciate that there are many well-known ways to functionally delete a gene product. For example, functional deletion can be accomplished by introducing one or more genetic modifications. As used herein, “genetic modifications” refer to any differences in the nucleic acid composition of a cell, whether in the cell's native chromosome or in endogenous or exogenous non-chromosomal plasmids harbored within the cell. Examples of genetic modifications that may result in a functionally deleted gene product include but are not limited to mutations such as substitutions, partial or complete deletions, insertions, or other variations to a coding sequence or a sequence controlling the transcription or translation of a coding sequence; placing a coding sequence under the control of a less active promoter; blocking transcription of the gene with a trans-acting DNA binding protein such as a TAL effector or CRISPR guided Cas9; and expressing ribozymes or antisense sequences that target the mRNA of the gene of interest, etc. In some versions, a gene or coding sequence can be replaced with a selection marker or screenable marker. Various methods for introducing the genetic modifications described above are well known in the art and include homologous recombination, among other mechanisms. See, e.g., Green et al., Molecular Cloning: A laboratory manual, 4^(th) ed., Cold Spring Harbor Laboratory Press (2012) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 3^(rd) ed., Cold Spring Harbor Laboratory Press (2001). Various other genetic modifications that functionally delete a gene product are described in the examples below. Functional deletion can also be accomplished by inhibiting the activity of the gene product, for example, by chemically inhibiting a gene product with a small molecule inhibitor, by expressing a protein that interferes with the activity of the gene product, or by other means.

In certain versions of the invention, the functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the non-functionally deleted gene product.

In certain versions of the invention, a cell with a functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the gene product compared to a cell with the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may be expressed at an amount less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the amount of the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more nonsynonymous substitutions are present in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more bases are inserted in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the gene product's gene or coding sequence is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a promoter driving expression of the gene product is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of an enhancer controlling transcription of the gene product's gene is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a sequence controlling translation of gene product's mRNA is deleted or mutated.

In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its unaltered state as found in nature. In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its form in a corresponding microorganism. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its unaltered state as found in nature. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its form in a corresponding microorganism.

As used herein, “corresponding microorganism” refers to a microorganism of the same species having the same or substantially same genetic and proteomic composition as a microorganism of the invention, with the exception of genetic and proteomic differences resulting from the modifications described herein for the microorganisms of the invention.

Some versions of the invention comprise microorganisms configured for increased production of pyruvate. For the production of pyruvate, at least three sets of enzymes are functionally deleted in the microorganism. Enzymes in a first set are selected from the group consisting of pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase. Enzymes in a second set are selected from the group consisting of phosphate acetyltransferase, acetate kinase, and pyruvate oxidase. Enzymes in a third set comprise lactate dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase; lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; or lactate dehydrogenase, one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase. Deletion of any gene or any other modification that reduces or ablates the activity of these enzymes or reduces or ablates flux of metabolites through these enzymes is encompassed by the present invention.

Pyruvate dehydrogenases convert pyruvate into acetyl Co-A. Pyruvate dehydrogenases include enzymes classified under any or all of EC 1.2.4.1, EC 2.3.1.12, and EC 1.8.1.4. An exemplary pyruvate dehydrogenase is the pyruvate dehydrogenase of E. coli, which is a multi-subunit complex comprising AceE (SEQ ID NO:2) encoded by aceE (SEQ ID NO:1), AceF (SEQ ID NO:4) encoded by aceF (SEQ ID NO:3), and Lpd (SEQ ID NO:6) encoded by lpdA (SEQ ID NO:5). AceE has activity classified under EC 1.2.4.1. AceF has activity classified under 2.3.1.12. Lpd has activity classified under 1.8.1.4. Other pyruvate dehydrogenases include homologs of the E. coli pyruvate dehydrogenase.

2-Oxoglutarate dehydrogenases convert α-ketoglutarate, NAD⁺, and CoA to succinyl CoA, CO₂, and NADH. 2-Oxoglutarate dehydrogenases include enzymes classified under any one or all of EC 1.8.1.4, EC 1.2.4.2, and EC 2.3.1.61. An exemplary 2-oxoglutarate dehydrogenase is the 2-oxoglutarate dehydrogenase of E. coli, which is a multi-subunit complex comprising Lpd (SEQ ID NO:6) encoded by lpdA (SEQ ID NO:5), SucA (SEQ ID NO:8) encoded by sucA (SEQ ID NO:7), and SucB (SEQ ID NO:10) encoded by sucB (SEQ ID NO:9). Lpd has activity classified under EC 1.8.1.4. SucA has activity classified under EC 1.2.4.2. SucB has activity classified under EC 2.3.1.61. Other 2-oxoglutarate dehydrogenases include homologs of the E. coli 2-oxoglutarate dehydrogenase. Functionally deleting 2-oxoglutarate dehydrogenase may be performed as an alternative to or in addition to functionally deleting pyruvate dehydrogenase.

Phosphate acetyltransferases convert acetyl-CoA and phosphate to CoA and acetyl phosphate. Phosphate acetyltransferases include enzymes classified under EC 2.3.1.8. An exemplary phosphate acetyltransferase is the phosphate acetyltransferase of E. coli (SEQ ID NO:12), which is encoded by pta (SEQ ID NO:11). Other phosphate acetyltransferases include homologs of the E. coli phosphate acetyltransferase.

Acetate kinases convert acetate and ATP to acetyl phosphate. Acetate kinases include enzymes classified under EC 2.7.2.-, such as EC 2.7.2.1. An exemplary acetate kinase is the acetate kinase A of E. coli (SEQ ID NO:14), which is encoded by ackA (SEQ ID NO:13). Other acetate kinases include homologs of the E. coli acetate kinase A. Functionally deleting acetate kinase may be performed as an alternative to or in addition to functionally deleting phosphate acetyltransferase. In some versions, the ackA gene in the microorganism is structurally and functionally intact such that the acetate kinase in the cells is fully expressed and fully functional.

Pyruvate oxidases convert pyruvate, phosphate, and O₂ to acetyl phosphate, CO₂, and H₂O₂. Pyruvate oxidases include enzymes classified under EC 1.2.3.3. An exemplary pyruvate oxidase is the pyruvate oxidase of E. coli (SEQ ID NO:16), which is encoded by poxB (SEQ ID NO:15). Other pyruvate oxidases include homologs of the E. coli pyruvate oxidase.

Lactate dehydrogenases convert pyruvate to lactate and vice versa. Lactate dehydrogenases include enzymes classified under any or all of EC 1.1.1.27 and EC 1.1.1.28. An exemplary lactate dehydrogenase is the LdhA of E. coli (SEQ ID NO:18), which is encoded by ldhA (SEQ ID NO:17). Other lactate dehydrogenases include homologs of the E. coli LdhA.

Cytochrome oxidases transfer electrons in the respiratory chain from donors to an acceptor. Cytochrome oxidases include enzymes classified under any or all of EC 1.9.3.1 and EC 1.10.3.-. Exemplary cytochrome oxidases suitable for functionally deleting in the present invention include cytochrome terminal oxidases, such as Family A cytochrome terminal oxidases. An exemplary Family A cytochrome terminal oxidase in E. coli is the cytochrome bo terminal oxidase, which is a multi-subunit complex comprising subunit I (SEQ ID NO:22) encoded by cyoB (SEQ ID NO:21), subunit II (SEQ ID NO:20) encoded by cyoA (SEQ ID NO:19), subunit III (SEQ ID NO:24) encoded by cyoC (SEQ ID NO:23), and subunit IV (SEQ ID NO:26) encoded by cyoD (SEQ ID NO:25). Subunits I-IV have activity classified under EC 1.10.3.-. A fifth gene of the cyo operon, cyoE (SEQ ID NO:27), encodes a heme 0 synthase (SEQ ID NO:28) that is essential for correct assembly of the complex and can be functionally deleted to effectively functionally delete the cytochrome bo terminal oxidase itself. Other cytochrome oxidases include homologs of the E. coli cytochrome bo terminal oxidase.

Succinate dehydrogenases catalyze the oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. Succinate dehydrogenases include enzymes classified under EC 1.3.5.1. An exemplary succinate dehydrogenase is the succinate dehydrogenase of E. coli, which is a multi-subunit complex comprising SdhA (SEQ ID NO:30) encoded by sdhA (SEQ ID NO:29), SdhB (SEQ ID NO:32) encoded by sdhB (SEQ ID NO:31), SdhC (SEQ ID NO:34) encoded by sdhC (SEQ ID NO:33), and SdhD (SEQ ID NO:36) encoded by sdhD (SEQ ID NO:35). Other succinate dehydrogenases include homologs of the E. coli succinate dehydrogenases.

6-Phosphogluconate dehydrogenases catalyze the decarboxylating reduction of 6-phosphogluconate into ribulose 5-phosphate in the presence of NADP⁺. Phosphogluconate dehydrogenases include enzymes classified under EC 1.1.1.44. An exemplary 6-phosphogluconate dehydrogenase is the Gnd of E. coli (SEQ ID NO:38), which is encoded by gnd (SEQ ID NO:37). Other 6-phosphogluconate dehydrogenases include homologs of the E. coli Gnd.

Glutamate dehydrogenases convert glutamate to α-ketoglutarate and vice versa. Glutamate dehydrogenases include enzymes classified under EC 1.4.1.4. An exemplary glutamate dehydrogenase is the GdhA of E. coli (SEQ ID NO:40), which is encoded by gdhA (SEQ ID NO:39). Other glutamate dehydrogenases include homologs of the E. coli GdhA.

In some versions of the invention, the microorganisms having the above-referenced sets of enzymes functionally deleted are evolved for enhanced production of pyruvate. The microorganisms are evolved by sequentially culturing microorganisms in media comprising decreasing concentrations of acetate. This process preferably involves sequentially culturing the microorganisms in aliquots of media, with sequential aliquots comprising decreasing concentrations of acetate. The concentrations of acetate in the media are preferably within a range of from about 0 mg/L to about 80 g/L, such as from about 0.001 mg/L to about 80 g/L, about 0.01 mg/L to about 50 g/L, about 0.1 mg/L to about 10 g/L, or about 0.1 mg/L to about 3 g/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 80 g/L and sequentially reduces to a concentration with a range of from about 0 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 80 g/L and sequentially reduces to a concentration with a range of from about 0.001 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 1 g/L and sequentially reduces to a concentration with a range of from about 0.1 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 500 g/L and sequentially reduces to a concentration with a range of from about 1 mg/L to about 90 mg/L.

The initial amount of total consumable carbon in the various media used in the sequential culturing is preferably approximately the same among the media. The initial amount of total consumable carbon preferably ranges from about 1 g/L to about 100 g/L, but may be higher or lower. Beyond the acetate, the balance of consumable carbon preferably comprises a sugar such as glucose or other carbohydrates or carbon sources known in the art. The sequential culturing may comprise passing the microorganism through the media in at least about 2, 3, 4, 5, 7, 10, 15, or 20 passages and/or up to about 5, 10, 15, 20, 30, 50 or more passages.

Some versions of the invention comprise microorganisms configured for increased production of ethanol. These microorganisms have the enzymes described above for producing pyruvate functionally deleted but additionally have pyruvate formate lyase functionally deleted.

Pyruvate formate lyases catalyze the reversible conversion of pyruvate and coenzyme-A into formate and acetyl-CoA. Pyruvate formate lyases include enzymes classified under EC 2.3.1.54. An exemplary pyruvate formate lyase is the PFL of E. coli (SEQ ID NO:42), which is encoded by pflB (SEQ ID NO:41). Other pyruvate formate lyases include homologs of the E. coli PFL.

In some versions of the invention, a pyruvate formate lyase activating enzyme in the recombinant microorganism is functionally deleted. Pyruvate formate lyase activating enzymes include enzymes classified under EC 1.97.1.4. Pyruvate formate lyase activating enzymes activate pyruvate formate lyases. Functionally deleting a pyruvate formate lyase activating enzyme constitutes a way to functionally delete a pyruvate formate lyase. An exemplary pyruvate formate lyase activating enzyme is the PFL activase of E. coli (SEQ ID NO:44), which is encoded by pflA (SEQ ID NO:43). Other pyruvate formate lyase activating enzymes include homologs of the E. coli PFL activase.

The enzymes described herein can be functionally deleted by mutating or disrupting expression of any one or all of the genes encoding the enzyme or its substituent subunits. Accordingly, the pyruvate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of aceE, aceF, and lpdA or homologs thereof. The 2-oxoglutarate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of lpdA, sucA, and sucB or homologs thereof. The phosphate acetyltransferase can be functionally deleted by mutating or disrupting expression of pta or homologs thereof. The acetate kinase can be functionally deleted by mutating or disrupting expression of ackA or homologs thereof. The pyruvate oxidase can be functionally deleted by mutating or disrupting expression of poxB or homologs thereof. The lactate dehydrogenase can be functionally deleted by mutating or disrupting expression of ldhA or homologs thereof. The cytochrome oxidase can be functionally deleted by mutating or disrupting expression of any one or more of cyoA, cyoB, cyoC, cyoD and cyoE or homologs thereof. The succinate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of sdhA, sdhB, sdhC, and sdhD or homologs thereof. The 6-phosphogluconate dehydrogenase can be functionally deleted by mutating or disrupting expression of gnd or homologs thereof. The glutamate dehydrogenase can be functionally deleted by mutating or disrupting expression of gdhA or homologs thereof. The pyruvate formate lyase can be functionally deleted by mutating or disrupting expression of pflB and pflA or homologs thereof.

The microorganisms of the invention may also be modified to increase expression of one or more enzymes. Modifying the microorganism to increase expression of an enzyme can be performed using any methods currently known in the art or discovered in the future. Examples include genetically modifying the microorganism and culturing the microorganism in the presence of factors that increase expression of the enzyme. Suitable methods for genetic modification include but are not limited to placing the coding sequence under the control of a more active promoter, increasing the copy number of the gene, introducing a translational enhancer on the gene (see, e.g., Olins et al. Journal of Biological Chemistry, 1989, 264(29):16973-16976), and/or increasing expression of transactivators. Increasing the copy number of the gene can be performed by introducing additional copies of the gene to the microorganism, i.e., by incorporating one or more exogenous copies of the native gene or a heterologous homolog thereof into the microbial genome, by introducing such copies to the microorganism on a plasmid or other vector, or by other means. “Exogenous” used in reference to a genetic element means the genetic element is introduced to a microorganism by genetic modification. “Heterologous” used in reference to a genetic element means that the genetic element is derived from a different species. A promoter that controls a particular coding sequence is herein described as being “operationally connected” to the coding sequence.

The microorganisms of the invention may include at least one recombinant nucleic acid configured to express or overexpress a particular enzyme. “Recombinant” as used herein with reference to a nucleic acid molecule or polypeptide is one that has a sequence that is not naturally occurring, has a sequence that is made by an artificial combination of two otherwise separated segments of sequence, or both. This artificial combination can be achieved, for example, by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules or polypeptides, such as genetic engineering techniques. “Recombinant” is also used to describe nucleic acid molecules that have been artificially modified but contain the same regulatory sequences and coding regions that are found in the organism from which the nucleic acid was isolated. A recombinant cell or microorganism is one that contains a recombinant nucleic acid molecule or polypeptide. “Overexpress” as used herein means that a particular gene product is produced at a higher level in one cell, such as a recombinant cell, than in a corresponding cell. For example, a microorganism that includes a recombinant nucleic acid configured to overexpress an enzyme produces the enzyme at a greater amount than a microorganism that does not include the recombinant nucleic acid.

Exogenous, heterologous nucleic acids encoding enzymes to be expressed in the microorganism are preferably codon-optimized for the particular microorganism in which they are introduced. Codon optimization can be performed for any nucleic acid by a number of programs, including “GENEGPS”-brand expression optimization algorithm by DNA 2.0 (Menlo Park, Calif.), “GENEOPTIMIZER”-brand gene optimization software by Life Technologies (Grand Island, N.Y.), and “OPTIMUMGENE”-brand gene design system by GenScript (Piscataway, N.J.). Other codon optimization programs or services are well known and commercially available.

Microorganisms of the invention configured to increase production of ethanol may be modified to increase expression of pyruvate decarboxylase and alcohol dehydrogenase.

Pyruvate decarboxylases catalyze the decarboxylation of pyruvic acid to acetaldehyde and carbon dioxide. Pyruvate decarboxylases include enzymes classified under EC 4.1.1.1. An exemplary pyruvate decarboxylase is the PDC of Zymomonas mobilis (SEQ ID NO:46), which is encoded by pdc (SEQ ID NO:45). Other pyruvate decarboxylases include homologs of the Z. mobilis PDC.

Alcohol dehydrogenases catalyze the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD⁺ to NADH). Alcohol dehydrogenases include enzymes classified under EC 1.1.1.1. An exemplary alcohol dehydrogenase is the ADH2 of Zymomonas mobilis (SEQ ID NO:48), which is encoded by adhB (SEQ ID NO:47). Other alcohol dehydrogenases include homologs of the Z. mobilis ADH2.

Increased expression of the pyruvate decarboxylase and/or the alcohol dehydrogenase can be included in a microorganism comprising a functional deletion of any of the genes or gene products, or combinations thereof, described herein.

Isocitrate lyase, encoded by aceA in E. coli or homologs thereof, can also be functionally deleted in any of the microorganisms described herein.

Homologs include genes or gene products (including enzymes) that are derived, naturally or artificially, from a common ancestral gene or gene product. Homology is generally inferred from sequence similarity between two or more genes or gene products. Homology between genes may be inferred from sequence similarity between the products of the genes. The precise percentage of similarity between sequences that is useful in establishing homology varies with the gene or gene product at issue, but as little as 25% sequence similarity (e.g., identity) over 50, 100, 150 or more residues (nucleotides or amino acids) is routinely used to establish homology (e.g., over the full length of the two sequences to be compared). Higher levels of sequence similarity (e.g., identity), e.g., 30%, 35% 40%, 45% 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more, can also be used to establish homology. Accordingly, homologs of the coding sequences, genes, or gene products described herein include coding sequences, genes, or gene products, respectively, having at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to the coding sequences, genes, or gene products, respectively, described herein. In some versions, homologs of the genes described herein include genes that have gene products at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical to the gene products of the genes described herein. Methods for determining sequence similarity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available. The homologous gene products should demonstrate comparable activities and, if an enzyme, participate in the same or analogous pathways. “Orthologs” are genes or coding sequences thereof in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same or similar function in the course of evolution. As used herein “orthologs” are included in the term “homologs.” Homologs also include paralogs.

For sequence comparison and homology determination, one sequence typically acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence based on the designated program parameters. A typical reference sequence of the invention is a nucleic acid or amino acid sequence corresponding to coding sequences, genes, or gene products described herein.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2008)).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity for purposes of defining homologs is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always>0) and N (penalty score for mismatching residues; always<0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=−4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. The above-described techniques are useful in identifying homologous sequences for use in the methods described herein.

The terms “identical” or “percent identity”, in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described above (or other algorithms available to persons of skill) or by visual inspection.

The phrase “substantially identical”, in the context of two nucleic acids or polypeptides refers to two or more sequences or subsequences that have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90, about 95%, about 98%, or about 99% or more nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. Such “substantially identical” sequences are typically considered to be “homologous” without reference to actual ancestry. Preferably, the “substantial identity” exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably, the sequences are substantially identical over at least about 150 residues, at least about 250 residues, or over the full length of the two sequences to be compared.

Accordingly, homologs of the genes described herein include genes with gene products at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or more identical to the gene products of the genes described herein.

The microorganisms of the invention may be prokaryotic, such as bacteria or archaea, or eukaryotic, such as yeast. Among bacteria, any bacterium in the domain Bacteria, the kingdom Eubacteria, the phylum Proteobacteria, the class Gammaproteobacteria, the order Enterobacteriales, and the family Enterobacteriaceae are suitable. Gram-positive, gram-negative, and ungrouped bacteria are suitable. Phototrophs, lithotrophs, and organotrophs are also suitable. In exemplary versions of the invention, the microorganism is E. coli. In some versions of the invention, the microorganism is a cyanobacterium. Suitable cyanobacteria include those from the genuses Agmenellum, Anabaena, Aphanocapsa, Arthrosprira, Gloeocapsa, Haplosiphon, Mastigocladus, Nostoc, Oscillatoria, Prochlorococcus, Scytonema, Synechococcus, and Synechocystis. Preferred cyanobacteria include those selected from the group consisting of Synechococcus spp., spp., Synechocystis spp., and Nostoc spp.

An aspect of the present invention includes methods of producing commodity chemicals, such as pyruvate and/or ethanol, with the microorganisms of the invention. The methods involve culturing the microorganism in conditions suitable for growth of the microorganism. Such conditions include providing suitable carbon sources for the particular microorganism along with suitable micronutrients. For eukaryotic microorganisms and heterotrophic bacteria, suitable carbon sources include various carbohydrates. Such carbohydrates may include biomass or other suitable carbon sources known in the art. For phototrophic bacteria, suitable carbon sources include CO₂, which is provided together with light energy. The commodity chemical can be purified or isolated with methods known in the art.

In some versions of the invention, the microorganism may be cultured in a medium comprising a biomass hydrolysate. The biomass hydrolysate can be produced from any biomass feedstock. Exemplary types of biomass feedstocks include sucrose-rich feedstocks such as suger cane; starchy materials, such as corn grain; and lignocellulosic biomass, such as costal Bermuda grass, corn cobs, corn stover, cotton seed hairs, grasses, hardwood stems, leaves, newspaper, nut shells, paper, primary wastewater solids, softwood stems, solid cattle manure, sorted refuse, swine waste, switchgrass, waste papers from chemical pulps, wheat straw, wood, and woody residues.

Prior to hydrolysis, the biomass feedstock may be pretreated or non-pretreated. Pretreatment of biomass feedstock removes a large proportion of the lignin and other materials and enhances the porosity of the biomass prior to hydrolysis. The biomass feedstock may be pretreated by any method. Exemplary pretreatments include chipping, grinding, milling, steam pretreatment, ammonia fiber expansion (AFEX, also referred to as ammonia fiber explosion), ammonia recycle percolation (ARP), CO₂ explosion, steam explosion, ozonolysis, wet oxidation, acid hydrolysis, dilute-acid hydrolysis, alkaline hydrolysis, organosolv, and pulsed electrical field treatment, among others. See, e.g., Kumar, P.; Barrett, D. M.; Delwiche, M. J.; Stroeve, P., Methods for Pretreatment of Lignocellulosic Biomass for Efficient Hydrolysis and Biofuel Production. Industrial & Engineering Chemistry Research 2009, 48, (8), 3713-3729.

The pretreated or non-pretreated biomass may be hydrolyzed by any suitable method. Hydrolysis converts biomass polymers to fermentable sugars, such as glucose and xylose, and other monomeric or oligomeric components. Exemplary hydrolysis methods include enzymatic hydrolysis (e.g., with cellulases or other enzymes) and acid hydrolysis (e.g., with sulfurous, sulfuric, hydrochloric, hydrofluoric, phosphoric, nitric, and/or formic acids), among other methods.

Exemplary biomass hydrolysates include AFEX-pretreated corn stover hydrolysate (ACSH) (Schwalbach et al. Appl. Environ. Microbiol. 2012, 78, (9), 3442-3457) and AFEX-pretreated switchgrass hydrolysate (ASGH).

The medium comprising the biomass hydrolysate may comprise at least about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99% biomass hydrolysate by volume or by mass.

The term “increase,” whether used to refer to an increase in production of an organic acid, an increase in expression of an enzyme, etc., generally refers to an increase from a baseline amount, whether the baseline amount is a positive amount or none at all.

The elements and method steps described herein can be used in any combination whether explicitly described or not.

The singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All patents, patent publications, and peer-reviewed publications (i.e., “references”) cited herein are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.

It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the following claims.

EXAMPLES

Overview

Microbes produce a variety of useful chemicals. However, most strains have not evolved to produce compounds at industrially-relevant levels. Metabolic engineering develops biocatalysts to produce desired chemicals at high rates, yields, and titers. Strains have been engineered to produce a broad range of products, including transportation fuels (e.g. ethanol, butanol and biodiesel) [1-5], pharmaceuticals (e.g. alkeloids, polyketides, nonribosomal peptides and isoprenoids) [6-11] and bulk and fine chemicals (e.g. amino acids, organic acids, industrial solvents and polymer precursors) [12-16]. Metabolic engineering strategies involve increasing production of pathway precursors, recycling redox carriers, improving flux through biosynthesis pathways, reducing toxic intermediate concentrations, and/or increasing tolerance to intermediates and products. Increasing precursor(s) supply is often needed to generate more of a desired downstream product. For example, strains with elevated malonyl-CoA levels were engineered to produce phloroglucinol (a polyketide derived from malonyl-CoA) [17], and strains with higher oxaloacetate levels produced more succinate, threonine and lysine, which are all derived from oxaloacetate[18].

Pyruvate is a central metabolite and precursor to acetyl-CoA and several amino acids (including alanine, lysine, valine, isoleucine and leucine). Commodity chemicals (e.g. ethanol, acetic acid, lactic acid and acrylic acid), as well as active pharmaceutical ingredients (e.g. polyketides and isoprenoids) can also be derived from pyruvate. Pyruvate can be converted into >60 commercial chemicals within five reaction steps. Furthermore, pyruvate itself can be used as a food additive, weight loss agent, and anti-aging skin treatment. Microbial production of pyruvate is an attractive alternative to current chemical processes, which are expensive and toxic [21].

Escherichia coli, Corynebacterium glutamicum, and Saccharomyces cerevisiae strains have been genetically engineered to produce pyruvate [19-24]. However, most strains have low yields and use expensive medium components. Previous E. coli metabolic engineering strategies focused on blocking pyruvate consumption pathways to phosphoenolpyruvate (PEP), acetyl-CoA, ethanol, acetate, lactate and formate. Other strategies prevented conversion of PEP to oxaloacetate by deleting PEP synthase, increasing glycolytic flux by deleting F1-ATPase deletion mutant or reducing NADH availability [19-21], and reducing TCA cycle fluxes by deleting α-ketoglutarate dehydrogenase [21]. The highest reported yield is 0.75 g pyruvate/g glucose (78% of the theoretical maximum yield) using a thiamin supplemented salts minimal medium. Pyruvate overproducing strains have been further altered to produce other chemicals, including alanine and diacetyl [25].

The present examples design and construct pyruvate strains using a genome-scale metabolic model of E. coli. OptORF [26] was used to search for gene deletions that would have high pyruvate yields at their maximal growth rate. Four mutant strains were constructed and characterized for growth and pyruvate production, and two of the four strains were adaptively evolved to increase growth rates and further improve pyruvate production. The pyruvate strains were further engineered to produce ethanol, which is derived from pyruvate. The examples show strains achieving up to 95% of the maximum theoretic yields for pyruvate. The examples also show growth and production of chemicals in bioreactors and with media containing biomass hydrolysate.

Materials and Methods

Strains and Plasmids

E. coli BW25113 and the pCP20 plasmid were obtained from the E. coli genetic stock center (CGSC, Yale University). Single E. coli gene deletion strains were obtained from the Keio collection (Open Biosystems) and used to construct multiple gene deletion strains (listed in Table 1). To generate mutants with multiple gene deletions, the kanamycin resistance gene (kan) was removed using the pCP20 plasmid [39]. An additional gene was deleted (and kan re-inserted) using P1 transduction from a donor Keio mutant and selection on LB agar plates with 50 μg/mL kanamycin. This process was repeated for each additional knockout and the gene deletions were verified by PCR. The GLBRCE1 strain, pJGG2 plasmid, and its corresponding empty vector (pBBR-DSC5) were obtained from Robert Landick (University of Wisconsin-Madison). The pJGG2 plasmid is a low copy number plasmid with a lac promoter that controls expression of the Zymomonas mobilis PET cassette genes (pdc and adhB) that encode enzymes to produce ethanol from pyruvate. GLBRCE1 lacks ldhA, pflB and ackA and contains pJGG2 and a chromosomal copy of the PET cassette inserted in the pflB locus [36].

Media and Culture Conditions

For shake flask and hungate tube experiments, M9 minimal media [44] supplemented with glucose and acetate (at varying concentrations) was used. Gentamicin was added to the media (at 15 μg/mL) for strains containing pJGG2 or pBBR-DSC5 plasmids. All strains were precultured overnight in Luria Broth (LB), pelleted and washed twice in M9 media, and then resuspended in M9 media with an initial OD600 of 0.01. For aerobic flask experiments, cultures were grown aerobically in 250 mL flasks containing 100 mL of media.

For anaerobic hungate tube experiments, cultures were grown in hungate culture tubes with 10 mL of media and IPTG was added (at 200 μM) to induce the expression of PET cassette. Hungate tubes were vacuumed and flushed with argon three times. All experiments were carried out in triplicate at 37° C. in a shaking incubator. Samples were periodically taken for further analysis and cells were removed using 0.2 μm nylon filter.

For aerobic bioreactor experiments, a minimal salts medium (adapted from [40]) was used that included 3.5 g/L KH₂PO₄, 5 g/L K₂HPO₄, 3.5 g/L (NH₄)₂HPO₄, 2 mM MgSO₄, 0.1 mM CaCl₂, 0.01 mM FeCl₃ and 0.5 mL per L trace metal solution (described previously [40]). Glucose (30 g/L) and acetate (at reported concentrations) were added to the minimal salts medium. AFEX-pretreated switchgrass hydrolysate (ASGH) was provided by the Great Lakes Bioenergy Research Center. The initial concentrations of glucose, xylose and acetate in ASGH hydrolysate were quantified by HPLC. Bioreactor seed cultures were prepared by inoculating 100 mL of minimal salts medium (with 30 g/L glucose and 0.9 g/L acetate) from a 5 mL overnight LB culture such that the initial OD600 was 0.01. Cells were grown at 37° C. for 14 hours in a 250-mL shake flask and then transferred into three 250-mL flasks containing 100 mL of same medium. The cultures were grown at 37° C. for another 8 hours and used to inoculate the bioreactors. The starting OD600 in the bioreactors was 0.05.

Bioreactors

Batch and fed-batch experiments were conducted in a 3 L bioreactor (Applikon Biotechonology, Inc., Shiedam, Netherlands) using a 1 L working volume with the following parameters 37° C., 0.5 L/min air inflow and pH 7.0±0.1. Acid (0.5 M H₂SO₄) and base (2 M KOH) buffers were added to adjust the pH as needed. The stifling speed was set to 500-800 rpm by a single Rushton impeller to ensure the dissolved oxygen level was above 40% of saturation. Each bioreactor experiment was conducted in duplicate. Samples were taken periodically for sugar and end-product analysis after cells were removed by centrifugation. For fed-batch experiments, a 200 g/L acetate solution was added to the reactor when growth slowed. For PYR020, the fed-batch started with 30 g/L glucose and 0.6 g/L acetate, and an additional 0.3 g/L acetate was added (1.5 mL of 200 g/L solution). For PYR004, the fed-batch started with 30 g/L glucose and 1.5 g/L acetate, and an additional 1.5 g/L acetate was added (7.5 mL of 200 g/L solution).

Chemical Analyses

Glucose concentrations were determined using an enzyme assay from Sigma (GAGO20). Pyruvate, lactate, acetate, succinate, and formate concentrations in the medium were measured by HPLC using an Aminex HPX-87H with Cation-H guard column (Bio-Rad, cat#125-0140). The mobile phase contained 0.02 N H₂SO₄ (for samples from minimal medium) or 0.05 N H₂SO₄ (for samples from ammonia fiber expansion (AFEX)-pretreated switchgrass hydrolysate (ASGH)) and was run at a flow rate of 0.5 mL/min at 50° C. The end-products were quantified (from standard curves) based on their refractive index. The reported yields were all adjusted by taking into account evaporation and buffer addition to bioreactors. The uptake and secretion rates were determined from the metabolite and biomass concentration data during exponential growth. Biomass concentrations (gram of cell dry weight per liter, gDW/L) were calculated from OD600 values using a conversion factor 1 OD600=0.415 gDW/L [41].

Adaptive Evolution

PYR001 and PYR002 were adaptively evolved independently for 20 passages. The initial cultures were grown in M9 minimal medium with 1.6 g/L glucose and 0.4 g/L acetate. At an OD600˜0.2, cells were transferred to fresh medium (such that starting OD600 was 0.01). During adaptive evolution, the amount of acetate in the medium was gradually reduced, while the glucose concentration increased so that the total carbon source was 2 g/L. After 15 passages, the medium contained 1.98 g/L glucose and 0.02 g/L acetate. Cultures from each passage were frozen and stored at −80° C.

Strain Design

OptORF was used to identify gene deletions that couple growth and pyruvate production [26]. This method finds mutants that would produce pyruvate at their highest biomass yield. OptORF was run using a tilted inner objective function (growth rate—0.001•pyruvate production rate) [42] and a gene deletion penalty equal to 1 in the outer objective function. All simulations were done for glucose aerobic conditions using the iJR904 E. coli genome-scale metabolic network [43], with a maximum glucose uptake rate of 10 mmol/gDW/hour and an unlimited oxygen uptake.

Results

In Silico Strain Design for Pyruvate Production

To improve pyruvate production, OptORF suggested four strategies which delete: (1) aceE, cyoA, cydB, pta, eutI, ldhA and dld; (2) lpdA, gnd, sdhA, poxB, pflB, pflD, tdcE and purU; (3) aceE, gdhA, poxB, ldhA, dld, atpE, pflB, pflD and tdcE; or (4) aceE, gnd poxB, ldhA, dld, atpE, pflB, pflD and tdcE (FIGS. 2A-2D). Given the large numbers of deletions, the identified genes were further evaluated and prioritized for deletion. Enzymes that are inactive under glucose aerobic conditions (e.g. due to regulation) were first excluded, including pyruvate formate lyases (PflB and PflD) [27, 28]. In addition, eutI, dld and tdcE encode minor isozymes for Pta, LdhA and PflB, respectively [29-32]. Deleting purU also had little impact on cell growth in glucose minimal media [33, 34]. Based on these considerations, pflB, pflD, eutI, dld, tdcE and purU were not deleted since they are likely to have low (if any) activity anyway. Additionally, the cydB and atpE deletions were experimentally lethal in combination with other suggested gene deletions (data not shown) and were not included in the constructed strains. The remaining genes identified by OptORF were deleted to create four engineered strains (PYR001-PYR004, Table 1).

The engineered strains each involved deletions that impacted metabolism and pyruvate production differently. Deleting aceE, lpdA, pta, poxB, and/or ldhA reduces the conversion of pyruvate into acetyl-CoA, acetate, and lactate. Deletion of cyoA, sdhA, and/or lpdA slows down the citric acid (TCA) cycle which would decrease ATP production, and thus biomass yields. With regard to gdhA and gnd, E. coli has two primary pathways for glutamate synthesis using NADPH, ammonia and α-ketoglutarate. The glutamate dehydrogenase (GDH) pathway (via gdhA) does not require ATP, while the other glutamine synthetase-glutamine oxoglutarate aminotransferase (GS-GOGAT) pathway consumes one ATP per glutamate formed. Deleting gdhA forces cells to use the GS-GOGAT pathway, increasing ATP consumption and decreasing biomass yields. Similarly, deleting gnd prevents NADPH production via the pentose phosphate pathway, and cells produce NADPH from NADH via pyridine nucleotide transhydrogenase. The transhydrogenase consumes energy, thereby lowering the maximum biomass yield. In both cases, lowering the maximum biomass yield (via gdhA or gnd deletions) will increase pyruvate yields, since pyruvate and biomass formation compete for carbon. The gene deletions either prevent pyruvate consumption or reduce growth, and synergistically enhance pyruvate production. Based on the computational results, four strains (PYR001-PYR004) were constructed and tested experimentally (see Table 1). The aceA deletion in PYR001 is not required.

TABLE 1 Strains and plasmids. Strains/Plasmid Genotype/Relevant characteristics Reference E. coli strains BW25113 lacI^(q) rrnBT14 ΔlacZWJ16 hsdR514 [39] ΔaraBADAH33 ΔrhaBADLD78 PYR001 BW25113 aceE::kan ΔcyoA Δpta This study ΔldhA ΔaceA PYR002 BW25113 lpdA::kan Δgnd ΔpoxB ΔsdhA This study PYR003 BW25113 aceE::kan ΔgdhA ΔpoxB ΔldhA This study PYR004 BW25113 aceE::kan Δgnd ΔpoxB ΔldhA This study PYR010 Adaptively evolved strain of PYR001 This study (single isolate) PYR020 Adaptively evolved strain of PYR002 This study (single isolate) GLBRCE1 MG1655 ΔackA ΔldhA ΔpflB::PET [36] crl(70insIS1) ylbE(253insG) gltB(G3384A) yodD(A85T) glpR(150delG) gatC(916insCC), pJGG2 EH010-pflB PYR010 ΔaceE pflB::kan pJGG2 This study EH020-pflB PYR020 ΔlpdA pflB::kan pJGG2 This study EH030-pflB PYR003 ΔaceE pflB::kan pJGG2 This study EH040-pflB PYR004 ΔaceE pflB::kan pJGG2 This study Plasmids pBBR1-MSC5 pBBR oriT; P_(lac); Gent^(R) [36] pJGG2 pBBR1-MSC5 with adhB and pdc (PET [36] cassette) from pLOI295; Gent^(R) Abbreviations: kan, kanamycin resistance gene; Gent^(R), gentamicin resistance. Characterization of Engineered Pyruvate Strains

Pyruvate production was characterized in the parent E. coli (BW25113) and four mutant strains PYR001, PYR002, PYR003 and PYR004 in M9 minimal medium supplemented with glucose (FIGS. 3A-3C). All mutant strains contain either an aceE or lpdA deletion, which prevents synthesis of acetyl-CoA from pyruvate via pyruvate dehydrogenase. As a result, acetate was added to the media for all four mutant strains to allow for acetyl-CoA synthesis and growth (Table 2). The four mutants grew slower than the parent strain, but produced pyruvate as predicted by the model (FIGS. 3A-3C), whereas the parent strain did not secrete any pyruvate. Strain PYR001 grew the slowest and only consumed ˜40% of glucose (˜4.0 mM) within 60 hours. However, PYR001 converted most of the glucose consumed to pyruvate (79% of the theoretical maximum yield, Table 2). Strains PYR003 and PYR004 both completed growth within 20 hours and produced 17.0 and 19.4 mM pyruvate, respectively (79% and 87% of theoretical maximum yield). Among the four mutants, PYR002 had the lowest pyruvate yield (43%) and also exhibited a slower growth rate.

The secretion of metabolic by-products, such as succinate, formate, acetate, lactate and ethanol, was analyzed using HPLC (FIG. 4). Acetate was the main byproduct of the parent strain (BW25113). PYR001 and PYR002 each produced ˜1 to 2 mM acetate (which was surprising since they required exogenous acetate for growth), while PYR003 and PYR004 consumed acetate, presumably for acetyl-CoA production. PYR002 was the only strain that produced lactate (˜9.8 mM), which explains its relatively low pyruvate yield. Succinate, formate, and ethanol were below the limits of detection by HPLC.

TABLE 2 Production of pyruvate from the parent and mutant strains in shake flasks. Pyruvate Yield Pyruvate Production Rate M9 Medium with Growth % of max. Conversion^(‡) Pyruvate Specific^(¶) Glucose Acetate Rate theoretical (g pyruvate/ Titer Volumetric (mmol/gDW/ Strains (g/L) (g/L) (hour⁻¹) yield^(†) g substrate) (g/L)^(§) (g/L/hour) hour) BW25113 2 0 0.59 ± 0.01 0 0 0 0 0 PYR001 1.9 0.1 0.02 ± 0.00 79.15 ± 4.63 0.78 ± 0.05 0.62 ± 0.04 0.01 ± 0.00  6.04 ± 0.24 PYR002 1.8 0.2* 0.12 ± 0.01 43.24 ± 2.89 0.43 ± 0.03 0.91 ± 0.06 0.02 ± 0.00  5.47 ± 0.04 PYR003 1.9 0.1 0.45 ± 0.03 79.05 ± 0.63 0.75 ± 0.00 1.50 ± 0.01 0.08 ± 0.00 20.36 ± 0.47 PYR004 1.9 0.1 0.30 ± 0.00 86.60 ± 4.12 0.82 ± 0.04 1.71 ± 0.08 0.07 ± 0.01 19.11 ± 0.25 PYR010 1.98 0.02 0.20 ± 0.04 68.33 ± 7.81 0.67 ± 0.08 1.39 ± 0.16 0.06 ± 0.00 14.91 ± 1.68 PYR020 1.98 0.02 0.34 ± 0.00 95.23 ± 3.12 0.92 ± 0.03 1.95 ± 0.06 0.05 ± 0.00 23.73 ± 0.88 *PYR002 required more acetate than other strains to start growth within 48 hour. ^(†)Percent of theoretical yield is calculated as the pyruvate concentration divided by the theoretical maximum production of pyruvate (2 mmol of pyruvate per mmol of glucose). Acetate was also taken account for calculating the theoretical maximum production (0.5 mmol of pyruvate per mmol of acetate). The yield was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions. ^(‡)Conversion is expressed as the gram of pyruvate produced per gram of total carbon source (including glucose and acetate). It was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions. ^(§)The reported titer is the concentration determined by HPLC (and does not account for evaporative loss). ^(¶)The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth. The numbers that follow the ± sign are standard deviations (SD) from triplicate experiments. Adaptive Evolution to Improve Pyruvate Productivity

Strains PYR003 and PYR004 showed high pyruvate productivity, while strains PYR001 and PYR002 exhibited low pyruvate yields and/or production rates. All four pyruvate producing strains were designed such that at their maximum growth rate pyruvate production would be high. Therefore, an adaptive evolution approach was used to evolve PYR001 and PYR002 and select for faster growth, which should also select for higher pyruvate rates. Adaptive evolution was conducted under aerobic conditions for 20 passages at 37° C. in glucose+acetate M9 minimal medium. Acetate was added to the medium to enable cell growth, but the concentration was reduced over adaptive evolution (Table 2). Single colonies of the evolved populations, containing progenies of PYR001 and PYR002, were isolated from the last passage and are referred to as PYR010 and PYR020, respectively. The evolved isolates' growth and pyruvate production were characterized (Table 2 and FIGS. 3D-F). The evolved strains had a 10-fold (PYR010) and 3-fold (PYR020) increase in growth rate and ˜2-fold increase in pyruvate titers (PYR010 and PYR020). In terms of pyruvate yield, PYR010 had a 10% lower yield than its unevolved strain (PYR001) while PYR020 had ˜2-fold increase (PYR020). Interestingly, both evolved strains needed less acetate (5-fold and 10-fold decrease) in the medium to support their growth. Among the four unevolved strains and two evolved strains, PYR020 performed best with respect to yield and titer, followed by PYR004. Both strains were selected for further characterization in bioreactors (Table 3).

Culture in High Concentration of Carbon Source and Lignocellulosic Biomass

Strains with high yields, titers and volumetric production rates are desired for industrial application. While our engineered strains achieved high yields in shake flasks, their titers and volumetric production rate were low due to the low glucose concentrations in the medium. Therefore, a minimal salts medium with higher glucose concentrations (30 g/L) was used to evaluate production by two of the higher yielding pyruvate strains (PYR020 and PYR004). Acetate was the limiting nutrient for both mutants, and thus two different concentrations were used in different experiments (0.9 g/L and 1.5 g/L for PYR020, and 1.5 g/L and 3 g/L for PYR004). Experiments were conducted in 1 L volume, pH-controlled bioreactors, and the dissolved oxygen level was kept above 40% of saturation to maintain an aerobic environment.

PYR020 and PYR004 were first grown in batch bioreactors in minimal salts media with 30 g/L glucose plus acetate. Both PYR004 and PYR020 had slightly higher growth rates, pyruvate yields and titers in media containing less acetate (1.5 g/L for PYR004 and 0.9 g/L for PYR020) (Table 3). For PYR004, higher acetate concentrations significantly reduced the time required to complete conversion of glucose to pyruvate (from ˜33 hours to ˜20 hours, FIG. 5). However, at the same acetate concentration (1.5 g/L) PYR020 was faster than PYR004 (FIG. 5, Panel (A), and FIG. 6, Panel (B)), presumably because PYR020 was evolved to grow at lower acetate concentrations. In batch conditions, both strains exhibited higher volumetric productivities when grown with higher acetate levels (Table 3). The two strains produce pyruvate at varying amounts during different stages of batch growth. PYR004 produced a large amount of pyruvate after growth stopped (˜27% and ˜63% of total pyruvate produced for 3 and 1.5 g/L acetate, respectively) (FIG. 5), while PYR020 produced most of the pyruvate during growth (˜91% and 71% for 1.5 and 0.9 g/L acetate, respectively) (FIG. 6). In addition, PYR020 had ˜33% higher specific pyruvate production rates (measured in mmol pyruvate/gDW/h) during exponential growth than PYR004 (Table 3).

Both strains were also grown in fed-batch bioreactors, where additional acetate was added once growth slowed. Compared to the batch results with the same total amount of acetate (0.9 g/L for PYR020 and 3 g/L for PYR004), both strains produced less pyruvate (˜1.9 and ˜2.2% lower yields for PYR020 and PYR004, respectively) in fed-batch experiments (Table 3, FIG. 5 and FIG. 6). However, both strains had higher volumetric pyruvate production rates when grown in fed-batch compared to batch growth with the same total amount of acetate. In both batch and fed-batch operation, tradeoffs appear to exist between volumetric productivities and pyruvate yields, with PYR004 tending to have higher volumetric productivities and PYR020 tending to have higher yields in the conditions tested (Table 3).

Since PYR020 had slightly higher pyruvate yields in minimal salts media than PYR004, PYR020 was further characterized in media derived from lignocellosic biomass. AFEX-pretreated switchgrass hydrolysate (ASGH) was used in batch bioreactor experiments, and contained 48 g/L glucose and 2.6 g/L acetate. The natural presence of acetate in ASGH (and other plant hydrolysates) meant no acetate supplementation was required. Compared to glucose minimal salts media, PYR020 had a similar exponential growth rate in ASGH (˜0.22 hour⁻¹), but entered into a slower linear growth phase after ˜20 hours (FIG. 7). Growth stopped at −80 hours, after all the glucose and most of the acetate (1.8 g/L) were utilized. However, xylose, another sugar present in ASGH, was hardly used. While pyruvate titers (40.7 g/L) and pyruvate yields (85.6%) were still high, the volumetric production rate was substantially lower in ASGH then minimal salts media due to slower growth (Table 3). Hydrolysates derived from lignocellulosic biomass contain microbial inhibitors (e.g., feruloyl amide) [35], whose presence reduces growth and xylose conversion. To further increase pyruvate production from lignocellulosic biomass, improvements in xylose conversion and inhibitor tolerance are likely needed.

TABLE 3 Production of pyruvate from the mutant strains in bioreactors. Pyruvate yield Pyruvate Production Rate Medium^(#) Growth % of max. Conversion^(‡) Pyruvate Specific^(¶) Bioreactor Glucose Acetate Rate theoretical (g pyruvate/ Titer Volumetric (mmol/gDW/ Strains Mode (g/L) (g/L) (hour⁻¹) yield^(†) g substrate) (g/L)^(§) (g/L/hour) hour) PYR020 Batch 30 0.9 0.25 ± 0.02 92.35 ± 0.41 0.89 ± 0.01 27.38 ± 0.16 1.01 ± 0.01 20.91 ± 1.60 PYR020 Batch 30 1.5 0.23 ± 0.00 89.95 ± 4.72 0.85 ± 0.05 26.85 ± 1.60 1.10 ± 0.07 20.06 ± 2.08 PYR020 Fed-batch 30 0.9 0.27 ± 0.02 90.61 ± 1.46 0.86 ± 0.02 26.73 ± 0.58 1.14 ± 0.02 24.17 ± 2.05 PYR004 Batch 30 1.5 0.56 ± 0.03 91.17 ± 0.02 0.87 ± 0.00 27.35 ± 0.01 0.88 ± 0.00 15.11 ± 4.61 PYR004 Batch 30 3.0 0.52 ± 0.01 86.63 ± 0.40 0.80 ± 0.01 26.36 ± 0.41 1.17 ± 0.02 11.45 ± 3.55 PYR004 Fed-batch 30 3.0 0.53 ± 0.03 84.70 ± 2.70 0.77 ± 0.01 25.32 ± 0.43 1.37 ± 0.02 17.09 ± 6.71 PYR020 Batch* 48 2.6 0.22 ± 0.02 85.63 ± 3.54 0.82 ± 0.04 40.74 ± 2.09 0.51 ± 0.04 26.36 ± 3.10 ^(#)The first six experiments were done in a minimal salts medium (not M9) supplemented with glucose and acetate (see methods for details). In the last experiment, the medium was ASGH hydrolysate which contained 48 g/L glucose, 27 g/L xylose and 2.6 g/L acetate (as determined by HPLC). ^(†)Percent of theoretical yield is calculated as the pyruvate concentration divided by the theoretical maximum production of pyruvate (2 mmol of pyruvate per mmol of glucose). Acetate was also taken account for calculating the theoretical maximum production (0.5 mmol of pyruvate per mmol of acetate). The yield was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions. ^(‡)Conversion is expressed as the gram of pyruvate produced per gram of total carbon source (including glucose and acetate). It was adjusted to account for the volume of added buffer to maintain the bioreactor at pH 7. ^(§)The reported titer is the concentration determined by HPLC (and does not account for the volume of added buffer). ^(¶)The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth. The numbers that follow the ± sign are standard deviations (SD) from duplicate bioreactor experiments. Production of Ethanol by PYR-Derived Strains

Pyruvate is a precursor to many metabolites, fuels, and chemicals. To test whether the engineered pyruvate strains could produce other chemicals, we further engineered the strains to convert pyruvate into ethanol. The pJGG2 plasmid was added which contains the PET cassette—pyruvate decarboxylase (pdc) and alcohol dehydrogenase (adhB)—from Zymomonas mobilis under the control of an IPTG inducible lac promoter. Ethanol production was measured under anaerobic conditions since producing ethanol recycles NADH generated by glycolysis. However, under anaerobic conditions pyruvate formate lyase (PflAB) converts pyruvate into acetyl-CoA and formate, and so pflB was additionally deleted from the pyruvate strains to create four ethanol strains: EH010-pflB, EH020-pflB, EH030-pflB and EH040-pflB.

Anaerobic fermentations in M9 minimal media supplemented with glucose (1.98 g/L) and acetate (0.02 g/L) were carried out in hungate tubes. Three control strains were included: the parent strain (BW25113) with empty vector (pBBR1-MSC5), parent strain with pJGG2 plasmid, and an ethanol production strain, GLBRCE1 (which lacks ackA, NW, and ldhA and expresses the PET cassette from the chromosome and pJGG2 plasmid [36]). In the parent strain, expressing the PET cassette using pJGG2 increased the growth rate, ethanol yield (by ˜66%), and ethanol production rate compared to the empty vector (Table 4). The improved growth and ethanol production is likely a result of enhanced NADH recycling. Compared to the parent strain with pJGG2, all strains engineered to produce ethanol (GLBRCE1, EH010-pflB, EH020-pflB, EH030-pflB and EH040-pflB) had lower growth rates (Table 4). Three mutants (EH020-pflB, EH030-pflB and EH040-pflB) had between ˜16% and ˜21% higher ethanol yields compared to the parent strain with pJGG2, and had similar yields to GLBRCE1 (FIG. 8A). Two of these mutants (EH020-pflB and EH040-pflB) had higher volumetric productivity than both GLBRCE1 and the parent strain with pJGG2 (Table 4). Additional fermentations were performed using medium with more acetate (0.1 g/L with 1.9 g/L glucose) and/or reduced sampling frequency, and the ethanol yields and byproduct concentrations did not appear to change when more acetate was supplemented (FIGS. 8A and 8B).

TABLE 4 Production of ethanol from the parent and mutant strains. Ethanol yield Ethanol Production Rate M9 Medium with % of max. Conversion^(‡) Specific^(¶) Growth Rate Glucose Acetate theoretical (g pyruvate/ Ethanol Volumetric (mmol/gDW/ Strains^(§) (hour⁻¹) (g/L) (g/L) yield^(†) g substrate) Titer (g/L) (g/L/hour) hour) BW25113 + 0.28 ± 0.00 2 0 38.04 ± 1.70 0.19 ± 0.01 0.39 ± 0.02 0.02 ± 0.00  6.26 ± 0.10 pBBR1- MSC5 BW25113 + 0.37 ± 0.02 2 0 63.06 ± 2.59 0.32 ± 0.01 0.64 ± 0.03 0.04 ± 0.00 11.71 ± 1.09 pJGG2 GLBRCE1 0.16 ± 0.02 2 0 82.21 ± 0.91 0.42 ± 0.01 0.83 ± 0.01 0.03 ± 0.00 16.08 ± 0.78 EH010-pflB 0.18 ± 0.01 1.98 0.02 61.81 ± 6.77 0.31 ± 0.03 0.62 ± 0.07 0.02 ± 0.00 16.61 ± 1.15 EH020-pflB 0.25 ± 0.02 1.98 0.02 80.23 ± 4.84 0.41 ± 0.02 0.81 ± 0.05 0.04 ± 0.00 23.10 ± 1.48 EH030-pflB 0.19 ± 0.05 1.98 0.02 79.47 ± 7.12 0.40 ± 0.04 0.80 ± 0.07 0.02 ± 0.00 19.29 ± 1.12 EH040-pflB 0.22 ± 0.03 1.98 0.02 84.59 ± 7.03 0.43 ± 0.04 0.85 ± 0.07 0.04 ± 0.00 22.37 ± 2.28 ^(§)Strains GLBRCE1, EH010-pflB, EH020-pflB, EH030-pflB, and EH040-pflB all contain pJGG2. ^(†)Percent of theoretical yield is calculated as the ethanol concentration divided by the theoretical maximum production of ethanol (2 mmol of ethanol per mmol of glucose). Acetate is also taken account for calculating the theoretical maximum production (0.67 mmol of ethanol per mmol of glucose). ^(‡)The conversion is expressed as the gram of ethanol produced per gram of carbon. ^(¶)The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth. The numbers that follow the ± sign are standard deviations (SD) from triplicate experiments. Discussion

Optimizing production of a specific metabolite usually involves increasing synthesis of its precursors. Pyruvate is a starting compound for synthesizing a variety of biofuels (e.g., ethanol, 1-butanol and isobutanol) and chemicals. A high-yield pyruvate producing strain has great potential for creating strains to produce valuable chemicals. In this study, a genome-scale metabolic model of E. coli and OptORF were used to identify gene deletion targets to improve pyruvate production. Strains constructed based on the computational predictions produced high levels of pyruvate and adaptive evolution of two strains increased pyruvate yields, titers and volumetric production rates. Further engineering of these platform pyruvate strains resulted in strains with high ethanol production.

All the designed strains over-produced pyruvate. The gene targets prevented pyruvate consumption by removing competing pathways and reduced growth by eliminating more energetically efficient routes for NADPH and glutamate production. The mutations involved shutting down the pentose phosphate pathway, reducing TCA cycle flux, and lowering biomass production (FIGS. 2A-2D). All of the mutants were predicted to have increased glycolytic fluxes and coupling between growth and pyruvate production. Two of the strains immediately exhibited high pyruvate yields, while two other strains were adaptively evolved to improve production rates and/or yields.

All the pyruvate strains have pyruvate dehydrogenase subunits deleted (either aceE or lpdA). The model predicted that other pathways (besides pyruvate-formate lyase) could be used to produce acetyl-CoA. Acetyl-CoA could be made from acetaldehyde via acetaldehyde dehydrogenase (MhpF), where acetaldehyde is produced by threonine degradation and other reactions. Acetyl-CoA could also be produced by 2-amino-3-ketobutyrate CoA ligase (Kbl) from threonine degradation. However, all of the mutants were unable to grow in the absence of acetate, suggesting that these other pathways are not active at high enough levels. Acetate was consumed by all the pyruvate strains, except PYR001, presumably to generate acetyl-CoA by acetyl-CoA synthetase. The amount of acetate available (0.34-3.4 mM) was greater than or close to the amount acetyl-CoA needed for biomass (estimated as the product of the biomass concentration and acetyl-CoA biomass requirement, which is 3.7 mmol acetyl-CoA per gDW) [37]. In the ethanol production study, the mutants with increased fluxes of ethanol synthesis were observed to grow faster, which is also probably caused by the generation of acetaldehyde and then converted to acetyl-CoA, while another possibility is the balancing of NADH.

When the resulting pyruvate strains were re-engineered for ethanol production, three of the resulting strains achieved high ethanol yields (EH020-pflB, EH030-pflB and EH040-pflB) under anaerobic conditions. Deleting pflB and expressing the PET cassette increased ethanol as expected, except for EH010-pflB. EH010-pflB (derived from PYR010), had the lowest yield of the mutants with pflB deletion and PET addition. Among all the strains tested, EH010-pflB is closest genetically to GLBRCE1. Both EH010-pflB and GLBRCE1 have ldhA, pta and pflB deletions. Even though EH010-pflB has two additional deletions, aceE and cyoA, neither gene would be expected to be expressed anaerobically [38]. Thus, the significantly lower ethanol yield in EH010-pflB compared with GLBRCE1 was unexpected. GLBRCE1 was derived from a closely-related background strain (MG1655, compared to BW25113) and has an extra chromosomal copy of the PET cassette. This additional copy of the PET cassette could lead to higher PET expression levels and ethanol production in GLBRCE1. When compared to EH010, EH010-pflB should have reduced formate production (which it does, see FIG. 8A) and increased availability of pyruvate. However, EH010-pflB and EH010 exhibited similar ethanol yields (FIG. 8A). For the EH010-pflB strain, only 80% of the carbon was recovered in the biomass and measured products (which is lower than the other strains) and so it is possible that some other metabolite (not detected by HPLC) was secreted by EH010-pflB.

Yeast and bacterial strains have previously been engineered for pyruvate production [20, 22-24]. The strains usually require additional nutrients besides glucose (e.g., yeast extract, tryptone, thiamine) which will increase the cost for commercial production. An E. coli strain TC44 was previously reported to show the highest pyruvate production with 78% of theoretical yield and 1.2 g/L/hour production rate, when supplemented with thiamine. Our strain, PYR020, uses only mineral salt medium and reaches significantly higher yield (92% of theoretical yield) and a high production rate of 1.01 g/L/hour. This strain also could utilize cheaper hydrolysate feedstock to produce pyruvate with a high yield and titer. While PYR020 requires acetate for growth, acetate is commonly found in lignocellulosic hydrolysates. The PYR020 and PYR004 strains have the highest pyruvate production yield reported so far, and will be an ideal platform to create new strains to produce other important chemicals derived from pyruvate.

REFERENCES

-   1. Ingram L O, Conway T, Clark D P, Sewell G W, Preston J F.     Genetic-Engineering of Ethanol-Production in Escherichia-Coli. Appl     Environ Microb. 1987; 53(10):2420-5. PubMed PMID:     WOS:A1987K354800024. -   2. Atsumi S, Hanai T, Liao J C. Non-fermentative pathways for     synthesis of branched-chain higher alcohols as biofuels. Nature.     2008; 451(7174):86-U13. doi: Doi 10.1038/Nature06450. PubMed PMID:     WOS:000252079300039. -   3. Steen E J, Kang Y S, Bokinsky G, Hu Z H, Schirmer A, McClure A,     et al. Microbial production of fatty-acid-derived fuels and     chemicals from plant biomass. Nature. 2010; 463(7280):559-U182. doi:     Doi 10.1038/Nature08721. PubMed PMID: WOS:000273981100055. -   4. Beller H R, Goh E B, Keasling J D. Genes Involved in Long-Chain     Alkene Biosynthesis in Micrococcus luteus. Appl Environ Microb.     2010; 76(4):1212-23. doi: Doi 10.1128/Aem.02312-09. PubMed PMID:     WOS:000274328900029. -   5. Schirmer A, Rude M A, Li X Z, Popova E, del Cardayre S B.     Microbial Biosynthesis of Alkanes. Science. 2010; 329(5991):559-62.     doi: DOI 10.1126/science. 1187936. PubMed PMID: WOS:000280483500035. -   6. Hawkins K M, Smolke C D. Production of benzylisoquinoline     alkaloids in Saccharomyces cerevisiae. Nat Chem Biol. 2008;     4(9):564-73. doi: Doi 10.1038/Nchembio.105. PubMed PMID:     WOS:000258597700015. -   7. Pfeifer B A, Admiraal S J, Gramajo H, Cane D E, Khosla C.     Biosynthesis of complex polyketides in a metabolically engineered     strain of E-coli. Science. 2001; 291(5509):1790-2. doi: DOI     10.1126/science.1058092. PubMed PMID: WOS:000167320600060. -   8. Siewers V, San-Bento R, Nielsen J. Implementation of     Communication-Mediating Domains for Non-Ribosomal Peptide Production     in Saccharomyces cerevisiae. Biotechnol Bioeng. 2010; 106(5):841-4.     doi: Doi 10.1002/Bit.22739. PubMed PMID: WOS:000280058800014. -   9. Ro D K, Paradise E M, Ouellet M, Fisher K J, Newman K L, Ndungu J     M, et al. Production of the antimalarial drug precursor artemisinic     acid in engineered yeast. Nature. 2006; 440(7086):940-3. doi: Doi     10.1038/Nature04640. PubMed PMID: WOS:000236736700042. -   10. Leonard E, Ajikumar P K, Thayer K, Xiao W H, Mo J D, Tidor B, et     al. Combining metabolic and protein engineering of a terpenoid     biosynthetic pathway for overproduction and selectivity control.     Proceedings of the National Academy of Sciences of the United States     of America. 2010; 107(31):13654-9. doi: DOI 10.1073/pnas.1006138107.     PubMed PMID: WOS:000280605900021. -   11. Asadollahi M A, Maury J, Patil K R, Schalk M, Clark A,     Nielsen J. Enhancing sesquiterpene production in Saccharomyces     cerevisiae through in silico driven metabolic engineering. Metab     Eng. 2009; 11(6):328-34. doi: DOI 10.1016/j.ymben.2009.07.001.     PubMed PMID: WOS:000272036700002. -   12. Park J H, Lee K H, Kim T Y, Lee S Y. Metabolic engineering of     Escherichia coli for the production of L-valine based on     transcriptome analysis and in silico gene knockout simulation.     Proceedings of the National Academy of Sciences of the United States     of America. 2007; 104(19):7797-802. doi: DOI     10.1073/pnas.0702609104. PubMed PMID: WOS:000246461500015. -   13. Fong S S, Burgard A P, Herring C D, Knight E M, Blattner F R,     Maranas C D, et al. In silico design and adaptive evolution of     Escherichia coli for production of lactic acid. Biotechnol Bioeng.     2005; 91(5):643-8. doi: Doi 10.1002/Bit.20542. PubMed PMID:     WOS:000231523600012. -   14. Zhang X L, Jantama K, Moore J C, Jarboe L R, Shanmugam K T,     Ingram L O. Metabolic evolution of energy-conserving pathways for     succinate production in Escherichia coli. Proceedings of the     National Academy of Sciences of the United States of America. 2009;     106(48):20180-5. doi: DOI 10.1073/pnas.0905396106. PubMed PMID:     WOS:000272254400012. -   15. Nakamura C E, Whited G M. Metabolic engineering for the     microbial production of 1,3-propanediol. Curr Opin Biotech. 2003;     14(5):454-9. doi: DOI 10.1016/j.copbio.2003.08.005. PubMed PMID:     WOS:000186448200002. -   16. Wierckx N J P, Ballerstedt H, de Bont J A M, Wery J. Engineering     of solvent-tolerant Pseudomonas putida S12 for bioproduction of     phenol from glucose. Appl Environ Microb. 2005; 71(12):8221-7. doi:     Doi 10.1128/Aem.71.12.8221-8227.2005. PubMed PMID:     WOS:000234417600072. -   17. Zha W J, Rubin-Pitel S B, Shao Z Y, Zhao H M. Improving cellular     malonyl-CoA level in Escherichia coli via metabolic engineering.     Metab Eng. 2009; 11(3):192-8. doi: DOI 10.1016/j.ymben.2009.01.005.     PubMed PMID: WOS:000265565300008. -   18. Ravi R. Gokarn M A E, Elliot Altman, inventor Pyruvate     carboxylase overexpression for enhanced production of     oxaloacetate-derived biochemicals in microbial cells 1999. -   19. Zhu Y H, Eiteman M A, Altman R, Altman E. High Glycolytic Flux     Improves Pyruvate Production by a Metabolically Engineered     Escherichia coli Strain. Appl Environ Microb. 2008; 74(21):6649-55.     doi: Doi 10.1128/Aem.01610-08. PubMed PMID: WOS:000260429600020. -   20. Tomar A, Eiteman M A, Altman E. The effect of acetate pathway     mutations on the production of pyruvate in Escherichia coli. Applied     Microbiology and Biotechnology. 2003; 62(1):76-82. doi: DOI     10.1007/s00253-003-1234-6. PubMed PMID: WOS:000184014000010. -   21. Causey T B, Shanmugam K T, Yomano L P, Ingram L O. Engineering     Escherichia coli for efficient conversion of glucose to pyruvate.     Proceedings of the National Academy of Sciences of the United States     of America. 2004; 101(8):2235-40. doi: DOI 10.1073/pnas.0308171100.     PubMed PMID: WOS:000220140400004. -   22. Xu G Q, Hua Q, Duan N J, Liu L M, Chen J. Regulation of thiamine     synthesis in Saccharomyces cerevisiae for improved pyruvate     production. Yeast. 2012; 29(6):209-17. doi: Doi 10.1002/Yea.2902.     PubMed PMID: WOS:000305078900002. -   23. Wang Z K, Gao C J, Wang Q, Liang Q F, Qi Q S. Production of     pyruvate in Saccharomyces cerevisiae through adaptive evolution and     rational cofactor metabolic engineering. Biochem Eng J. 2012;     67:126-31. doi: DOI 10.1016/j.bej.2012.06.006. PubMed PMID:     WOS:000310945100017. -   24. Wieschalka S, Blombach B, Eikmanns B J. Engineering     Corynebacterium glutamicum for the production of pyruvate. Applied     Microbiology and Biotechnology. 2012; 94(2):449-59. doi: DOI     10.1007/s00253-011-3843-9. PubMed PMID: WOS:000302035500014. -   25. Mark A. Eiteman E A, inventorMicrobial production of pyruvate     and pyruvate derivatives patent US 20,100,304,450. 2012. -   26. Kim J, Reed J L. OptORF: Optimal metabolic and regulatory     perturbations for metabolic engineering of microbial strains. Bmc     Syst Biol. 2010; 4. doi: Artn 53 Doi 10.1186/1752-0509-4-53. PubMed     PMID: WOS:000278257700002. -   27. Peng L, Shimizu K. Global metabolic regulation analysis for     Escherichia coli K12 based on protein expression by 2-dimensional     electrophoresis and enzyme activity measurement. Applied     Microbiology and Biotechnology. 2003; 61(2):163-78. doi: DOI     10.1007/s00253-002-1202-6. PubMed PMID: WOS:000182702800011. -   28. Sawers G, Watson G. A glycyl radical solution: oxygen-dependent     interconversion of pyruvate formate-lyase. Molecular Microbiology.     1998; 29(4):945-54. doi: DOI 10.1046/j.1365-2958.1998.00941.x.     PubMed PMID: WOS:000075451700002. -   29. Bologna F P, Campos-Bermudez V A, Saavedra D D, Andreo C S,     Drincovich M F. Characterization of Escherichia coli EutD: a     Phosphotransacetylase of the Ethanolamine Operon. J Microbiol. 2010;     48(5):629-36. doi: DOI 10.1007/s12275-010-0091-0. PubMed PMID:     WOS:000283630100012. -   30. Zhou L, Zuo Z R, Chen X Z, Niu D D, Tian K M, Prior B A, et al.     Evaluation of Genetic Manipulation Strategies on d-Lactate     Production by Escherichia coli. Curr Microbiol. 2011; 62(3):981-9.     doi: DOI 10.1007/s00284-010-9817-9. PubMed PMID:     WOS:000287754500044. -   31. Tarmy E M, Kaplan N O. Kinetics of Escherichia Coli B D-Lactate     Dehydrogenase and Evidence for Pyruvate-Controlled Change in     Conformation. Journal of Biological Chemistry. 1968; 243(10):2587-&.     PubMed PMID: WOS:A1968B201700019. -   32. Sawers G, Hesslinger C, Muller N, Kaiser M. The glycyl radical     enzyme TdcE can replace pyruvate formate-lyase in glucose     fermentation. Journal of Bacteriology. 1998; 180(14):3509-16. PubMed     PMID: WOS:000074720100003. -   33. Nagy P L, Marolewski A, Benkovic S J, Zalkin H.     Formyltetrahydrofolate Hydrolase, a Regulatory Enzyme That Functions     to Balance Pools of Tetrahydrofolate and One-Carbon Tetrahydrofolate     Adducts in Escherichia-Coli. Journal of Bacteriology. 1995;     177(5):1292-8. PubMed PMID: WOS:A1995QJ43900023. -   34. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al.     Construction of Escherichia coli K-12 in-frame, single-gene knockout     mutants: the Keio collection. Mol Syst Biol. 2006; 2. doi: Artn     2006.0008 Doi 10.1038/Msb4100050. PubMed PMID: WOS:000243245400009. -   35. Mills T Y, Sandoval N R, Gill R T. Cellulosic hydrolysate     toxicity and tolerance mechanisms in Escherichia coli. Biotechnol     Biofuels. 2009; 2. doi: Artn 26 10.1186/1754-6834-2-26. PubMed PMID:     WOS:000272095400002. -   36. Schwalbach M S, Keating D H, Tremaine M, Marner W D, Zhang Y P,     Bothfeld W, et al. Complex Physiology and Compound Stress Responses     during Fermentation of Alkali-Pretreated Corn Stover Hydrolysate by     an Escherichia coli Ethanologen. Appl Environ Microb. 2012;     78(9):3442-57. doi: Doi 10.1128/Aem.07329-11. PubMed PMID:     WOS:000302807500047. -   37. Neidhardt F C, John L. Ingraham, and Moselio Schaechter.     Physiology of the bacterial cell: a molecular approach. Sunderland,     Mass.: Sinauer Associates; 1990. -   38. Toya Y, Nakahigashi K, Tomita M, Shimizu K. Metabolic regulation     analysis of wild-type and arcA mutant Escherichia coli under nitrate     conditions using different levels of omics data. Molecular     bioSystems. 2012; 8(10):2593-604. Epub 2012/07/14. doi:     10.1039/c2mb25069a. PubMed PMID: 22790675. -   39. Datsenko K A, Wanner B L. One-step inactivation of chromosomal     genes in Escherichia coli K-12 using PCR products. Proceedings of     the National Academy of Sciences of the United States of America.     2000; 97(12):6640-5. doi: DOI 10.1073/pnas.120163297. PubMed PMID:     WOS:000087526300074. -   40. Causey T B, Zhou S, Shanmugam K T, Ingram L O. Engineering the     metabolism of Escherichia coli W3110 for the conversion of sugar to     redox-neutral and oxidized products: Homoacetate production.     Proceedings of the National Academy of Sciences of the United States     of America. 2003; 100(3):825-32. doi: 10.1073/pnas.0337684100.     PubMed PMID: WOS:000180838100014. -   41. Baumler D J, Peplinski R G, Reed J L, Glasner J D, Perna N T.     The evolution of metabolic networks of E. coli. Bmc Syst Biol. 2011;     5:182. doi: Artn 182 Doi 10.1186/1752-0509-5-182. PubMed PMID:     WOS:000297698400001. -   42. Feist A M, Zielinski D C, Orth J D, Schellenberger J, Herrgard M     J, Palsson B O. Model-driven evaluation of the production potential     for growth-coupled products of Escherichia coli. Metab Eng. 2010;     12(3):173-86. doi: DOI 10.1016/j.ymben.2009.10.003. PubMed PMID:     WOS:000276821400001. -   43. Reed J L, Vo T D, Schilling C H, Palsson B O. An expanded     genome-scale model of Escherichia coli K-12 (iJR904 GSM/GPR). Genome     Biol. 2003; 4(9). doi: Artn R54 Doi 10.1186/Gb-2003-4-9-R54. PubMed     PMID: WOS:000185048100007. -   44. Miller, J. H. Experiments in Molecular Genetics. Cold Spring     Harbor Laboratory, (1972), 433. 

We claim:
 1. A microorganism comprising activity-reducing or activity-ablating mutations in endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, a lactate dehydrogenase, and one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase.
 2. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a 6-phosphogluconate dehydrogenase.
 3. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a glutamate dehydrogenase.
 4. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a 6-phosphogluconate dehydrogenase and an endogenous gene encoding a glutamate dehydrogenase.
 5. The microorganism of claim 1 further comprising an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.
 6. The microorganism of claim 1 wherein the microorganism is modified to express a pyruvate decarboxylase and an alcohol dehydrogenase.
 7. The microorganism of claim 1 wherein the microorganism comprises one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.
 8. The microorganism of claim 7 further comprising an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.
 9. The microorganism of claim 1 wherein the activity-reducing or activity-ablating mutations in the endogenous genes are independently selected from the group consisting of a nucleotide substitution in the endogenous gene, a nucleotide insertion in the endogenous gene, a partial deletion of the endogenous gene, and a complete deletion of the endogenous gene.
 10. The microorganism of claim 1 wherein the microorganism is a bacterium or a yeast.
 11. The microorganism of claim 1 wherein the microorganism is a bacterium.
 12. The microorganism of claim 1 wherein the microorganism is an evolved microorganism produced by sequentially culturing a precursor microorganism in media comprising decreasing concentrations of acetate, wherein the precursor microorganism comprises activity-reducing or activity-ablating mutations in (a) endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, and a lactate dehydrogenase, and (b) one or more endogenous genes encoding one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase, wherein the evolved microorganism exhibits one or more of increased growth rate compared to the precursor microorganism and increased pyruvate production compared to the precursor microorganism, and wherein the evolved microorganism comprises the activity-reducing or activity-ablating mutations in the endogenous genes of (a) and (b).
 13. The microorganism of claim 12 wherein the concentrations of acetate in the media in which the precursor microorganism is sequentially cultured to produce the microorganism range from about 0.1 mg/L acetate to about 3 g/L acetate.
 14. The microorganism of claim 12 wherein the evolved microorganism further comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.
 15. The microorganism of claim 12 wherein the evolved microorganism is modified to express a pyruvate decarboxylase and an alcohol dehydrogenase.
 16. The microorganism of claim 12 wherein the evolved microorganism comprises one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.
 17. A method of producing a chemical comprising culturing the microorganism of claim
 1. 18. The method of claim 17 wherein the microorganism further comprises: an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme; and one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.
 19. The method of claim 17 wherein the culturing comprises culturing the microorganism in a medium, the chemical is selected from the group consisting of pyruvate and ethanol, and the method further comprises purifying the chemical from the medium.
 20. The method of claim 17 wherein the culturing comprises culturing the microorganism in a medium comprising a biomass hydrolysate.
 21. The method of claim 17 wherein the microorganism is an evolved microorganism produced by sequentially culturing a precursor microorganism in media comprising decreasing concentrations of acetate, wherein the precursor microorganism comprises activity-reducing or activity-ablating mutations in (a) endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, and a lactate dehydrogenase, and (b) one or more endogenous genes encoding one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase, wherein the evolved microorganism exhibits one or more of increased growth rate compared to the precursor microorganism and increased pyruvate production compared to the precursor microorganism, and wherein the evolved microorganism comprises the activity-reducing or activity-ablating mutations in the endogenous genes of (a) and (b). 